Project Grant R43HL174670
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded The Ohio State University a $765,931 Project Grant on August 22, 2025. This grant will fund a multi-center hybrid effectiveness-implementation trial to assess the delivery of patient-facing, evidence-based guidelines for sickle cell disease (SCD) through a mobile health (mHealth) application and educational booklets. The goal is to improve knowledge and adherence to...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...
- This Project Grant award, totaling $169,444, was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to develop and pilot test a stress management intervention for Black adults with hypertension. The project will work with patients receiving care from federally-qualified health centers to iteratively design an intervention that addresses patient preferences and aims to promote cardiovascular health. Key outcomes to be examined include...
- This federal Project Grant award of $708,678, provided by the National Heart, Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to conduct a Sequential Multiple Assignment Randomized Trial (SMART) to reduce food insecurity and improve adherence in patients with hypertension. The key products and services to be delivered under this grant include: Determining the most effective initial food insecurity intervention (resource information or community health worker...
- This $500,000 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of the Hemotago HATS-OFF (Hemotag Assessment for Short-Term Outcomes of Heart Failure) technology by Aventusoft LLC, a small disadvantaged business in Boca Raton, Florida. The HATS-OFF system provides a non-invasive, at-home method for long-term monitoring of heart failure patients to detect decompensation early and enable timely therapy...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $585,794 to Tele-Stethoscope Inc., a self-certified small disadvantaged business, to develop a novel mobile phone technology that can detect preeclampsia and hypertension. The key products to be delivered under this award include: Proof-of-concept demonstration that ordinary mobile phones can accurately reproduce a physician's diagnosis of preeclampsia....
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will evaluate the use of mobile devices to extract vital signs to monitor patients with asthma. The $459,127 award to M5 Enterprise, LLC (doing business as Emedical Sentry) aims to improve the detection and management of asthma attacks through remote patient monitoring. The goal is to enhance telehealth by incorporating video-based vital sign...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $538,998 Project Grant to Texas A&M AgriLife Research under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The 4-year "Deep in the Heart" project aims to develop and evaluate a community-engaged intervention to prevent obesity and cardiovascular disease risk factors in rural South Texas women. The project will involve formative research, a multilevel intervention including group classes, a...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is providing $731,130 to the Children's Hospital Medical Center to conduct a study titled "Improving Medication Adherence Using an Adaptive mHealth Intervention in Adolescents with Asthma". The study aims to evaluate the effectiveness of a stepped-care mHealth intervention for improving adherence to daily inhaled corticosteroids in adolescents with asthma. The...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,153 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Safebeat RX Inc. The funding supports the development of a novel, smartwatch-enabled technology that allows patients with low-risk atrial fibrillation to safely initiate antiarrhythmic medications at home. The technology analyzes post-drug ECG data taken by patients using a machine learning algorithm and provides this information to...
This federal Project Grant award of $498,576.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to enhance the FAITH! mobile health application to promote cardiovascular health among African Americans. The funding will be used by the small business awardee, Careevolution LLC, in partnership with Mayo Clinic, to analyze participant feedback from a previous clinical trial evaluating the web-based FAITH! app intervention. The goal is to optimize the app's usability, acceptability, and satisfaction for users. This work builds on prior research demonstrating the FAITH! app's efficacy in improving cardiovascular health behaviors among African American participants. By enhancing the mobile app platform, the project seeks to extend the reach and scalability of the FAITH! program's culturally tailored digital health intervention.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $498.6k | 8/14/25 |